Taiwan biotech firm eyes Hong Kong IPO for push into mainland China market for cornea transplants

ACRO Biomedical, a Taiwan-based developer of skin, bone and cornea graft materials, plans to restructure via a reverse takeover and seek an initial public share offer in Hong Kong so that it can tap into the mainland China market. The company, based in …
( read original story …)

Search your Hotel